ArticleNature2020
Pharmacologic fibroblast reprogramming into photoreceptors restores vision.
Open access · greenAbstract read
In one paragraph
Article in Nature, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers.
0numbers the graph read from it
0cells of the map it votes in
62citing papers in PubMed
6.2field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
62 citing papers in PubMed, 108 citations in OpenAlex.
- Trends in neuroprosthetic technologies to restore sensations.Biomedical engineering letters · 2026Review
- Co-Evaporated Ratio-Tunable TeSmall (Weinheim an der Bergstrasse, Germany) · 2026Article
- Direct reprogramming of Müller glia into photoreceptors via multiple transcription factors and small molecules: molecular mechanisms and transcriptomic analysis.In vitro cellular & developmental biology. Animal · 2026Article
- Axin1 stabilizes S-opsin and maintains cone photoreceptor survival by inhibiting GSK3β activity.Cell death discovery · 2026Article
- Histone methyltransferase Setd8 preserves chromatin accessibility to safeguard retinal progenitor cell identity during development.Stem cell reports · 2026Article
- Article
- Cell and tissue reprogramming: Unlocking a new era in medical drug discovery.Pharmacological reviews · 2025Review
- Effects of different anesthetic drugs on electroretinography in mice.Scientific reports · 2025Article
- Investigating Müller glia reprogramming in mice: a retrospective of the last decade, and a look to the future.Neural regeneration research · 2025Article
- Review
- Recent advances in photothermal nanomaterials for ophthalmic applications.Beilstein journal of nanotechnology · 2025Review
- Transplantation of derivative retinal organoids from chemically induced pluripotent stem cells restored visual function.NPJ Regenerative medicine · 2024Article
- Recent progress of principal techniques used in the study of Müller glia reprogramming in mice.Cell regeneration (London, England) · 2024Review
- Using Small Molecules to Reprogram RPE Cells in Regenerative Medicine for Degenerative Eye Disease.Cells · 2024Review
- Assessment of visual function in blind mice and monkeys with subretinally implanted nanowire arrays as artificial photoreceptors.Nature biomedical engineering · 2024Article
- Article
- A metabotropic glutamate receptor agonist enhances visual signal fidelity in a mouse model of retinitis pigmentosa.bioRxiv : the preprint server for biology · 2024Article
- Review
- Rapid and efficient generation of a transplantable population of functional retinal ganglion cells from fibroblasts.Cell proliferation · 2024Article
- Generating Retinas through Guided Pluripotent Stem Cell Differentiation and Direct Somatic Cell Reprogramming.Current stem cell research & therapy · 2024Review
2 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
16 authors at 3 institutions in 1 country.
Biraj MahatoDepartment of Pharmacology and Neuroscience, Laboratory for Retinal Rehabilitation, North Texas Eye Research Institute, University of North Texas Health Science Center, Fort Worth, TX, USA.
Koray Dogan Kaya *Neurobiology, Neurodegeneration and Repair Laboratory, National Eye Institute, National Institutes of Health, Bethesda, MD, USA.
Yan Fan *Department of Pharmacology and Neuroscience, Laboratory for Retinal Rehabilitation, North Texas Eye Research Institute, University of North Texas Health Science Center, Fort Worth, TX, USA.
Nathalie SumienDepartment of Pharmacology and Neuroscience, University of North Texas Health Science Center, Fort Worth, TX, USA.ORCID http://orcid.org/0000-0002-0077-9873
Ritu A ShettyDepartment of Pharmacology and Neuroscience, University of North Texas Health Science Center, Fort Worth, TX, USA.
Wei ZhangDepartment of Pharmacology and Neuroscience, Laboratory for Retinal Rehabilitation, North Texas Eye Research Institute, University of North Texas Health Science Center, Fort Worth, TX, USA.
Delaney DavisDepartment of Pharmacology and Neuroscience, University of North Texas Health Science Center, Fort Worth, TX, USA.
Thomas MockDepartment of Pharmacology and Neuroscience, University of North Texas Health Science Center, Fort Worth, TX, USA.
Subrata BatabyalNanoscope Technologies LLC, Bedford, TX, USA.
Aiguo NiDepartment of Pharmacology and Neuroscience, Laboratory for Retinal Rehabilitation, North Texas Eye Research Institute, University of North Texas Health Science Center, Fort Worth, TX, USA.
Samarendra MohantyNanoscope Technologies LLC, Bedford, TX, USA.
Zongchao HanDepartment of Ophthalmology, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.ORCID http://orcid.org/0000-0002-2019-395X
Rafal FarjoEyeCRO LLC, Oklahoma City, OK, USA.
Michael J ForsterDepartment of Pharmacology and Neuroscience, University of North Texas Health Science Center, Fort Worth, TX, USA.
Anand SwaroopNeurobiology, Neurodegeneration and Repair Laboratory, National Eye Institute, National Institutes of Health, Bethesda, MD, USA.
Sai H ChavalaDepartment of Pharmacology and Neuroscience, Laboratory for Retinal Rehabilitation, North Texas Eye Research Institute, University of North Texas Health Science Center, Fort Worth, TX, USA. schavala@gmail.com.
University of North Texas · USNational Institutes of Health · USUniversity of North Carolina at Chapel Hill · US
Funding
Regulation of retinal developmentZIAEY000450 · NEI · NATIONAL EYE INSTITUTE · PI SWAROOP, ANAND · 2009 to 2025
$71.0MMechanisms, modeling and therapies of retinal and macular neurodegenerationZIAEY000546 · NEI · NATIONAL EYE INSTITUTE · PI SWAROOP, ANAND · 2015 to 2025
$36.3MInterventional approaches for restoring visionZIAEY000474 · NEI · NATIONAL EYE INSTITUTE · PI SWAROOP, ANAND · 2009 to 2019
$15.5MTraining in the Neurobiology of Aging and Alzheimer's DiseaseT32AG020494 · NIA · UNIVERSITY OF NORTH TEXAS HLTH SCI CTR · PI ROBERT Clinton BARBER, NATHALIE SUMIEN · 2002 to 2026
$6.9MAMBIENT LIGHT ACTIVATABLE OPSIN BASED THERAPY FOR AGE-RELATED MACULAR DEGENERATIONR44EY025905 · NEI · NANOSCOPE TECHNOLOGIES, LLC · PI MOHANTY, SAMARENDRA KUMAR · 2018 to 2022
$3.7MBioluminescent Multi-Characteristic Opsin for simultaneous optical stimulation and large-scale monitoring of the visual systemR01EY028216 · NEI · NANOSCOPE TECHNOLOGIES, LLC · PI MOHANTY, SAMARENDRA KUMAR · 2018 to 2022
$2.0MHigh-throughput bioengineering technologies for vision restorationR01EY025667 · NEI · UNIVERSITY OF NORTH TEXAS HLTH SCI CTR · PI CHAVALA, SAI HEMANTH · 2015 to 2019
$1.8MBroad-band opsin and targeted optical-delivery for retinitis pigmentosa treatmentR01EY025717 · NEI · NANOSCOPE TECHNOLOGIES, LLC · PI MOHANTY, SAMARENDRA KUMAR · 2016 to 2020
$1.7MRegulation of adult ciliary body progenitor cells for cell replacement therapyK08EY021171 · NEI · UNIV OF NORTH CAROLINA CHAPEL HILL · PI CHAVALA, SAI HEMANTH · 2011 to 2015
$1.2MAmbient light activatable opsin based therapy for age-related macular degenerationR43EY025905 · NEI · NANOSCOPE TECHNOLOGIES, LLC · PI WRIGHT, WELDON · 2015 to 2016
$260kIntramural NIH HHS ZIA EY000450Intramural NIH HHS ZIA EY000474Intramural NIH HHS ZIA EY000546NEI NIH HHS K08 EY021171NEI NIH HHS R01 EY025667NEI NIH HHS R01 EY025717NEI NIH HHS R01 EY028216NEI NIH HHS R43 EY025905NEI NIH HHS R44 EY025905NIA NIH HHS T32 AG020494
Abstract
Photoreceptor loss is the final common endpoint in most retinopathies that lead to irreversible blindness, and there are no effective treatments to restore vision
Indexed as
AnimalsAxin ProteinBasic Helix-Loop-Helix ProteinsCellular ReprogrammingDisease Models, AnimalFibroblastsFlow CytometryMiceMitochondriaNF-kappa BProtein TransportReactive Oxygen SpeciesRetinal DegenerationRetinal Rod Photoreceptor CellsSignal TransductionVision, OcularAscl1 protein, mouseAxin2 protein, mouseAxin ProteinBasic Helix-Loop-Helix ProteinsNF-kappa BReactive Oxygen Species
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.